IOVA Q4 2021 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$99M

Net Income

-$99M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$61M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$777M

Total Liabilities

$156M

Stockholders' Equity

$622M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$99M	-$69M	-45.1%
Net Income	-$99M	-$68M	-45.2%